Official websites use. Share sensitive information only on official, secure websites. Node-positive prostate cancer is a potentially curable disease. Definitive radiotherapy to the prostate and lymphatic drainage is an effective treatment option but prospective long-term outcome data are scarce.
Thus, the current study aimed to evaluate the toxicity and efficacy of definitive radiation therapy for men with prostate cancer and nodal metastases using modern irradiation techniques. All patients received definitive radiation therapy at two German university hospitals between and Feasibility and safety, overall and progression-free survival, toxicity, and quality of life measurements were analyzed.
During a median follow-up of 79 months, median overall survival was months and progression-free survival was 78 months.
Based on imaging follow-up, no infield relapse was reported during the first 24 months of follow-up. Common iliac node involvement was associated with a higher risk of progression HR Location rather than number of involved nodes is a major risk factor for progression. The online version of this article Keywords: Regional and distant metastasis, Radiotherapy, Pelvic lymph node, Toxicity, Quality of life.
With an incidence of per , males per year, prostate cancer is the most common newly diagnosed noncutaneous cancer in European men [ 1 ]. In case of node-positive prostate cancer at primary diagnosis, the mainstay of treatment is either radical prostatectomy with pelvic lymph node dissection or definitive radiation to the prostate and pelvic nodes both combined with androgen-deprivation therapy [ 2 ].
